Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

61.22 -1.12 (-1.80%)
Official Closing Price Updated: 7:00 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,425,294
Open 61.57
Bid (Size) 61.02 (100)
Ask (Size) 61.51 (100)
Prev. Close 62.34
Today's Range 60.43 - 61.95
52wk Range 42.52 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 4.12%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
+14.5%
+14.5%
1 Month
+9.5%
+9.5%
3 Month
+26.9%
+26.9%
6 Month
+29.1%
+29.1%
1 Year
+2.3%
+2.3%

More News

Read More
News headline image
How to Spot Winning Innovation ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗
Via The Motley Fool
Topics Energy Lawsuit
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors ↗
Via Chartmill
News headline image
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
Via MarketMinute
Topics Economy Intellectual Property
News headline image
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
From Bristol Myers Squibb
Via Business Wire
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Via FinancialNewsMedia
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
Via MarketMinute
Topics Intellectual Property
News headline image
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm
Via StockStory
News headline image
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Incredibly Cheap Dividend Stocks to Buy Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Stocks to Buy and Hold for 2026 and Beyond ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
Via MarketMinute
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
Via Finterra
Topics Lawsuit
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
News headline image
The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
Via Finterra
Topics Economy Intellectual Property
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Via Finterra
Topics Economy Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 61.22
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 03/03/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 136.04B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 136B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.